- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03182049
Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study (NoAAC PR-03)
Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease: North American Airway Collaborative (NoAAC) PR-03 Study
The ultimate goal of this prospective natural history study is to define the natural history of the obstructive airway manifestations of Granulomatosis with polyangiitis (GPA).
Additionally this proposal seeks to develop biomarkers of disease activity and define their correlation with clinical outcomes in an effort to transform clinical care and shape future drug development for this devastating rare disease.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Granulomatosis with polyangiitis (GPA, formerly known as Wegener's granulomatosis) is a rare multisystem necrotizing granulomatous vasculitis of small and medium vessels. Nearly 20% of GPA patients suffer life-threatening obstruction of their airways. Even when survived, airway involvement can render patients in this disease subset unable to communicate, struggling to breath, and dependent on a tracheostomy for survival. Airway disease frequently leads to irreversible physiologic impairment and is highly correlated with reduced quality of life in GPA.
Prior to the 1970s, patients with GPA had a 1-year mortality rate of >80%, primarily due to renal or lung failure. The introduction of combination cyclophosphamide and glucocorticoid treatment 4 decades ago greatly improved patient outcomes, turning this into a more chronic long-term disease. However, while progress has been made in the development of successful treatment regimes for systemic disease, the role of current therapies in ameliorating the airway complications of GPA is unknown. The evolution of GPA into a chronic disease has brought the management of the airway manifestations of GPA to the forefront. The natural history of the airway disease in GPA has never been longitudinally characterized, and there are no reliable biomarkers of clinical outcome.
In GPA the incidence of airway stenosis localized to the anatomic region below the vocal cord (subglottic stenosis) has been estimated to be 16%-50%. It may occur in isolation as the presenting symptom of GPA, or as a late-stage manifestation of disease. Although stenosis is frequently limited to the subglottis, it may extend up to involve to vocal cords, or down to involve the distal trachea and bronchi. Unfortunately, studies have documented a relatively high incidence of multilevel airway involvement (34%) in GPA. In one series of 44 patients, one in five had evidence of laryngeal stenosis. Studies have also found a high incidence of metachronous bronchial disease.
Laryngeal and Bronchial stenosis appear to be progressive and occur after the onset of subglottic stenosis, but the true natural history of airway involvement in GPA is unknown.
GPA is a member of the anti-neutrophil cytoplasmic antibody (ANCA) vasculitides. Given the strong association of GPA with ANCA production, much focus has been placed on understanding the mechanisms of ANCA production and pathogenesis. The factors by which ANCAs are initially generated are poorly understood. The majority of in vitro and animal model research implicating neutrophils and T cells as the principal inflammatory cells in GPA is surprising given the known impressive clinical treatment response to B cell depletion with rituximab. This discordance reinforces that the knowledge gap between pathogenesis and therapy is GPA is wide.
The distinction between focused airway disease and severe systemic disease has important therapeutic implications. The course of airway stenosis in GPA has been found to run independently of the systemic disease course and is often refractory to standard systemic therapy. In one representative case series, subglottic stenosis (SGS) was diagnosed in 49% of patients while they were receiving systemic treatment, and 56% of the patients who required tracheostomies did so despite having been treated for at least 2 months with systemic immunosuppressive agents. Developing novel therapeutics to control airway-focused GPA and prevent the development and/or progression of destructive airway damage is desperately needed.
Because of the small numbers of patients affected, and with clinical experience dispersed among a small number of clinical referral centers, the natural history of rare diseases is often poorly described. When knowledge about disease is insufficient to guide clinical development, well-designed natural history studies are critical to developing and proving the efficacy of novel therapeutics.
Study Type
Contacts and Locations
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Greater than or equal to 18 years of age.
- Stenotic Airway Disease (laryngeal, subglottic, distal tracheal or bronchial)
Exclusion Criteria:
- <18years of age
- Patients without capacity to consent for themselves
- History of significant laryngotracheal traumatic injury.
- Endotracheal intubation 2 years prior to presentation.
- Major anterior neck surgery.
- History of neck irradiation.
- History of caustic or thermal injury to the laryngotracheal complex.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
GPA (Wegener's granulomatosis) patients
|
Airway Specialist (Otolaryngology, Pulmonology, Thoracic Surgery), assess clinical location and degree of airway compromise, glottic mobility, and sinonasal disease.
Clinically assess systemic function (renal/pulmonary ect), biochemical profile (routine labs), neurocognitive function, and completing entry BVAS tool.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to recurrent intervention (TTR)
Time Frame: 5 years
|
The time between interventions aimed at preserving an open airway.
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Reported Outcome Measures
Time Frame: 5 years
|
Patient Quality of Life assessment: Voice (VHI10)
|
5 years
|
Patient Reported Outcome Measures
Time Frame: 5 years
|
Patient Quality of Life assessment: Breathing (Clinical Dyspnea questionnaire or CDQ)
|
5 years
|
Patient Reported Outcome Measures
Time Frame: 5 years
|
Patient Quality of Life assessment: Eating (EAT10)
|
5 years
|
Patient Reported Outcome Measures
Time Frame: 5 years
|
Patient Quality of Life assessment: general quality of life (SF12)
|
5 years
|
Disease Assessment clinical tool
Time Frame: 5 years
|
Birmingham Vasculitis Activity Score (BVAS)
|
5 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Alexander Gelbard, MD, Vanderbilt University Medical Center
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 161780
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Granulomatosis With Polyangiitis
-
Hospital for Special Surgery, New YorkRoche Pharma AG; Genentech, Inc.TerminatedGranulomatosis With Polyangiitis (Wegener's Granulomatosis)United States
-
Assistance Publique - Hôpitaux de ParisFrench Vasculitis Study GroupCompletedEosinophilic Granulomatosis With Polyangiitis (EGPA)France
-
University of PennsylvaniaUniversity of South Florida; University of OxfordCompletedVasculitis | Churg-Strauss Syndrome (CSS) | Microscopic Polyangiitis (MPA) | Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA) | Granulomatosis With Polyangiitis (Wegener's) (GPA) | Wegener Granulomatosis (WG) | ANCA-Associated Vasculitis (AAV)United States
-
InflaRx GmbHIqvia Pty LtdTerminatedGranulomatosis With Polyangiitis (GPA) | Microscopic Polyangiitis (MPA)United States, Canada
-
InflaRx GmbHCompletedGranulomatosis With Polyangiitis (GPA) | Microscopic Polyangiitis (MPA)Germany, Russian Federation, Belgium, France, Spain, Czechia, Italy, Netherlands, Sweden, Switzerland, United Kingdom
-
Imperial College LondonAstraZenecaEnrolling by invitationEGPA - Eosinophilic Granulomatosis With PolyangiitisUnited Kingdom
-
University of PennsylvaniaNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompletedMicroscopic Polyangiitis (MPA) | Granulomatosis With Polyangiitis (Wegener's) (GPA)United States, Belgium, France, United Kingdom, Denmark, Canada, Japan, Australia, New Zealand, Sweden, Czechia, Italy, Greece, Mexico, Norway
-
University of South FloridaNational Heart, Lung, and Blood Institute (NHLBI); National Institute of Arthritis... and other collaboratorsActive, not recruitingVasculitis | Granulomatosis With Polyangiitis | Wegener GranulomatosisUnited States
-
University of South FloridaBristol-Myers Squibb; University of Pennsylvania; National Institute of Arthritis... and other collaboratorsActive, not recruitingWegener's Granulomatosis | Granulomatosis With Polyangiitis | ANCA-Associated Vasculitis | Granulomatosis With Polyangiitis (Wegener's)United States, United Kingdom, Ireland, Canada, Germany
-
Portsmouth Hospitals NHS TrustCompletedChurg-Strauss SyndromeUnited Kingdom
Clinical Trials on Airway assessment
-
University Hospitals Coventry and Warwickshire...Completed
-
Norwegian University of Science and TechnologyUniversity of Copenhagen; Haukeland University Hospital; St. Olavs HospitalCompletedPulmonary Disease, Chronic ObstructiveNorway
-
Rajiv Gandhi Cancer Institute & Research Center...CompletedVocal Cord Movement Assessment by Airway UltrasoundIndia
-
University of JenaCompleted
-
Kasr El Aini HospitalCompletedFiberoptic Tracheal Intubation
-
Cairo UniversityCompletedEndotracheal Intubation
-
Johannes Gutenberg University MainzCompletedAirway Complication of AnesthesiaGermany
-
Diskapi Teaching and Research HospitalRecruitingGastric Insufflation | Difficult Mask VentilationTurkey
-
University of SaskatchewanUnknownAnesthesia, GeneralCanada
-
University of VermontUnknownAirway Obstruction | Respiratory ComplicationUnited States